Product Search

#10909 Anti- CD134/OX40 (B7-B5) Mouse IgG MoAb

  • WB
  • FCM1
  • FCM2
Intended Use：
Research reagents
Application：
WB, IP, FCM
Package Size1：
500 μg
Package Size2：
100 μg
Note on Application Abbreviations
WB:Western Blotting
IP:Immunoprecipitation
FCM:Flow Cytometry

※ The product indicated as "Research reagents" in the column Intended Use cannot be used
　 for diagnostic nor any medical purpose.
※ The datasheet listed on this page is sample only. Please refer to the datasheet
　 enclosed in the product purchased before use.

Product Overview

Product Overview

Product Code 10909
Product Name Anti- CD134/OX40 (B7-B5) Mouse IgG MoAb
Intended Use Research reagents
Application WB, IP, FCM
Immunizing antigen Recombinant soluble OX40
Source Mouse-Mouse hybridoma　(SP2/0 × BALB/c mouse spleen cells)
Clone Name B7-B5
Subclass IgG1
Purification Method Gel filtration chromatography following ammonium sulfate precipitation
Package Form Lyophilized product from PBS containing 1 % BSA and 0.05 % NaN3
Storage Condition 2 - 8℃
Poisonous and Deleterious Substances Applicable
Cartagena Not Applicable
Package Size 1 500 μg
Package Size 2 100 μg
Remarks1 The commercial use of products without our permission is prohibited. Please make sure to contact us and obtain permission.

Product Description

Product Description

CD134/OX40 is a receptor of OX40 ligand (OX40L) transactivated by Tax of HTLV-1. OX40 is expressed in activated CD4+ and CD8+ T cells. OX40 on the activated T cells have a role in proliferation of T cells and production of cytokines by binding with OX40L expressed on antigen presenting cells like dendritic cells or activated B cells. In addition, it also be involved in activated T cell invasion to inflamed area through the binding with OX40L.

FAQ

FAQ

  • Question
    Q.Can this antibody be used for human T cell?
  • Answer
    A.Yes, it can. This antibody was used in the following publication. Please refer to it.

    Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells.
    Kondo K et al. Hum Immunol. 2007 Jul;68(7):563-71. Epub 2007 Apr 13.
Contact Us >